Eco R1 Capital, LLC Macrogenics Inc Transaction History

Eco R1 Capital, LLC

$2.31 Billion
Q3 2024

A detailed history of Eco R1 Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Eco R1 Capital, LLC holds 56,018 shares of MGNX stock, worth $181,498. This represents 0.01% of its overall portfolio holdings.

Number of Shares

56,018

Holding current value

$181,498

% of portfolio

0.01%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $168,054 - $310,899	56,018 New	56,018 $184,000
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $2.4 Million - $3.61 Million	-498,263 Reduced 44.59%	619,192 $4.44 Million
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $622,910 - $1.3 Million	186,500 Added 20.03%	1,117,455 $7.5 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $2.8 Million - $4.86 Million	930,955 New	930,955 $3.22 Million
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $17.4 Million - $31.7 Million	-1,481,086 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $587,044 - $715,060	30,480 Added 2.1%	1,481,086 $31.8 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $5.85 Million - $10.1 Million	309,812 Added 27.16%	1,450,606 $36.5 Million
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $18.5 Million - $23.2 Million	1,140,794	1,140,794 $21.7 Million

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

Bellevue Group Ag Kuesnacht, V8

9.93M
Shares

$32.2 Million
0.55% of portfolio
Armistice Capital, LLC New York, NY

6.26M
Shares

$20.3 Million
0.34% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$17.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.36M
Shares

$14.1 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.54M
Shares

$11.5 Million
0.01% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.

Account